DB15682ApprovedInvestigationalVaccines
This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. It is approved for use in individuals 10...
- Primary indication
- This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.Curator reviewed
- First approval
- Canada, 2020 · United States, 2020 · European Union, 2021
- Also known as
- Nimenrix component neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which companies are running trials of Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account